Mainstream

Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion

Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion

Post ContentalnyRead More

You might also be interested in reading Bitcoin Price Rebounds, But Could the Downtrend Return?.

February 14, 2025
In Mainstream